EP Patent

EP3798222A1 — Crystalline form of lorlatinib free base

Assigned to Pfizer Inc · Expires 2021-03-31 · 5y expired

What this patent protects

This invention relates to a pharmaceutical composition comprising a crystalline form of (10 R )-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2 H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7…

USPTO Abstract

This invention relates to a pharmaceutical composition comprising a crystalline form of (10 R )-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2 H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7) and methods of using such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.

Drugs covered by this patent

Patent Metadata

Patent number
EP3798222A1
Jurisdiction
EP
Classification
—
Expires
2021-03-31
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.